Your AI-Trained Oncology Knowledge Connection!
Ginseng is an herb from the genus Panax of the Araliaceae family that is an important part of traditional Chinese medicine (TCM). It is termed an “adaptogen,” as it is believed to have properties that help to restore balance to the body and protect the body from physiologic stress.
English and Spanish PDFs
Register to be able to access the wonderful content on this site. Your FREE registration entitles you to a, b, c and helps earn a donation to Doctors without Borders.
“Comparative effectiveness research, ” or CER, has become a loaded term in our ongoing wrangling over healthcare policy. Often, however, what even knowledgeable people understand by CER is significantly at odds with what actual policy makers have in mind.
Kava is a plant indigenous to the Pacific Rim and the Hawaiian Islands whose root and rhizome are used to prepare a non-fermented beverage with relaxant effects that is used for social and recreational purposes.
CancerNetwork and the journal ONCOLOGY present exclusive hematology coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Follow the stories below and check back for more write-ups of the most important information to come out of this year's event.
The question of whether men with low-risk prostate cancer should have their cancers vigilantly monitored is an ongoing issue for the National Comprehensive Cancer Network (NCCN) Panel on prostate cancer.
A long-term and large-scale retrospective study of cancer patients who have undergone radiotherapy show that only a small portion of secondary cancers develop due to radiotherapy treatments.
Donald M. Berwick, the Director of Centers for Medicare and Medicaid Services (CMS) of the Health and Human Services Department as of March 2010, has written a perspective on the accountable care organizations (ACOs) of the Medicare Shares Savings Program.
An ethnographic study of palliative care specialists reveals that many of them find dealing with dying patients a gratifying experience. The scant evidence about oncologists on this subject paints a much different picture.
Speaking at the ACCC last Friday, Sean Tunis, founder and director of the Center for Medical Technology Policy, gave a basic primer on what he sees as the primary goal of comparative effectiveness research.
The Journal of Clinical Oncology published a paper ahead of print on March 21, 2011 that shows no increased risk of venous thromboembolisms (VTEs) when bevacizumab was added to chemotherapy compared to chemotherapy alone.
The National Comprehensive Cancer Network presented the first treatment algorithm for post-transplant lymphoproliferative disorder (PTLD) at the 16th annual NCCN's Conference on Clinical Practice Guidelines and Quality.
At the Association for Community Cancer Centers annual national meeting in Washington, DC this past March, the session on “Oncology Care in 2021” featured three panelists with significant experience in shaping healthcare policy.
The US Food and Drug Administration (FDA) on March 25 approved ipilimumab (Yervoy, Bristol-Myers Squibb) as immunotherapy for patients with late-stage melanoma, based studies showing it improved survival outcomes in these difficult-to-treat patients.
The Oncology Group of UBM Medica, publisher of ONCOLOGY, ONCOLOGY Nurse Edition, and Oncology NEWS International, and the website, cancernetwork.com, is pleased to present Cancer Management: A Multidisciplinary Approach, 13th edition.
As we learn more about the network of cellular pathways that function in the proliferation of cancer cells, it is becoming abundantly clear that there is no “magic bullet” cancer treatment. Janet Woodcock highlights the goals and current developments at the FDA to progress the combination clinical trial process
The American Society of Clinical Oncology (ASCO) updated its recommendation last month on the role of bone-modifying agents in the prevention of skeletal-related events (SREs) for metastatic breast cancer patients with bone metastases.
In North America, hepatocellular carcinoma (HCC) is one of only a few malignancies with an increasing incidence in recent years.[1]
The diagnosis and treatment of hepatocellular carcinoma (HCC) constitute a complex and challenging clinical paradigm.
Emerging as one of the many pieces to the puzzle is the adoption of pathways based on evidence-based medicine (EBM). It has long been theorized that the use of standardized care models not only improves the quality of care, but also reduces costs and makes costs more predictable.
The review by Drs. Boumber and Issa of epigenetic drugs that target human cancers nicely summarizes recent progress in this hot area and points out future lines of investigation.
Boumber and Issa provide a useful review of the development of agents that target the epigenome-primarily DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors.
More than 30 states are now either pursuing or contemplating legislation that will increase healthcare cost transparencies, and three bills relating to cost transparencies were introduced in Congress in 2010. Unfortunately, research on the effects of price transparency on healthcare systems is in its infancy, and little information is available for states to make these important legislative decisions.
In this review article we will discuss the current data on, and future role of, sorafenib in the treatment of hepatocellular carcinoma beyond Child-Pugh A cirrhosis, in conjunction with local therapy, and in a transplant setting.
The understanding that epigenetic changes are prevalent in cancer and play a causative role in its biology has led to the development of new therapeutic approaches that target the epigenetic machinery.
